SCHEMBL33565

SCHEMBL33565

CCCNC(C)=N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3523034 0.97
SCHEMBL4075630 0.82
SCHEMBL4555309 0.80
SCHEMBL19398814 0.78 MMP1 (0.33)
SCHEMBL18621827 0.78 EPHX1 (0.56)
SCHEMBL18560409 0.78 EPHX1 (0.56)
SCHEMBL12993988 0.78 EPHX1 (0.56)
SCHEMBL1273741 0.78 MMP1 (0.40)
SCHEMBL17641727 0.75
SCHEMBL4755259 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023166349-A2 PHENYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF 杭州百诚医药科技股份有限公司 2023-09-07 WO disclosed
WO-2023168367-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS IMMUNESENSOR THERAPEUTICS, INC. (US) 2023-09-07 WO disclosed
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146511-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146513-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023066292-A1 TRICYCLIC BORONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海济煜医药科技有限公司 2023-04-27 WO disclosed
WO-2022133069-A1 PEPTIDOMIMETIC MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. (US) 2022-06-23 WO disclosed
WO-2021239117-A1 MODIFIED PROTEINS AND PROTEIN DEGRADERS CULLGEN (SHANGHAI) , INC. (CN) 2021-12-02 WO disclosed
WO-2021141789-A1 STABLE FORMULATIONS OF ANTI-CANCER PEPTIDES ONCOLYZE, INC. (US) 2021-07-15 WO disclosed
WO-2021127452-A1 COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2021-06-24 WO disclosed
US-20090019645-A1 UNKNOWN L'OREAL S.A. (FR) 2009-01-22 US disclosed
US-20080244838-A1 Composition for the coloring of keratinous fibers comprising a halochromic compound and/or the dye corresponding to this compound, and method of use thereof L'OREAL S.A. (FR) 2008-10-09 US disclosed
US-20080235883-A1 Composition for the coloring of keratinous fibers comprising a halochromic compound, the dye corresponding to this compound, and methods of use thereof L'OREAL S.A. (FR) 2008-10-02 US disclosed
US-7413746-B2 Stent coatings containing self-assembled monolayers ADVANCED CARDIOVASCULAR SYSTEMS, INC. (US) 2008-08-19 US disclosed
US-20080189878-A1 Dyeing process using a dye of styryl or imine type in combination with a weak acid, and device for implementing the process L'OREAL S.A. (FR) 2008-08-14 US disclosed
WO-2008042928-A2 OXADIAZOLE AND THIADIAZOLE DERIVATIVES AS MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. (US) 2008-04-10 WO disclosed
US-20070218246-A1 Stent coatings containing self-assembled monolayers ADVANCED CARDIOVASCULAR SYSTEMS, INC. 2007-09-20 US disclosed
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-02-15 US disclosed
US-5264448-A Thioamides, oxazole ring, insecticides, miticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-11-23 US disclosed
EP-0394043-A1 An amide compound and its production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-10-24 EP disclosed